Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivo I de Vos

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Personalized Medicine|April 28, 2023
Active Surveillance for Prostate Cancer: Past, Current, and Future TrendsIvo I de Vos, Henk B Luiting, Monique J Roobol
European Urology|November 2, 2023
Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer RotterdamIvo I de Vos, Sebastiaan Remmers, Renée Hogenhout, et al.
European Urology|April 7, 2023
A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate CancerIvo I de Vos, Annick Meertens, Renée Hogenhout, et al.
European Urology Oncology|September 10, 2023
From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of LifeRenée Hogenhout, Sebastiaan Remmers, Marlies E van Slooten-Midderigh, et al.
European Urology Open Science|August 1, 2022
Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer RotterdamRenée Hogenhout, Ivo I de Vos, Sebastiaan Remmers, et al.
European Urology Oncology|November 27, 2024
Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer RotterdamIvo I de Vos, Charlotte Rosenstand, Renée Hogenhout, et al.
European Urology Open Science|April 14, 2025
Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller TumorsLisa J Kroon, Ivo I de Vos, Charlotte F Kweldam, et al.
JAMA Network Open|January 17, 2025
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active SurveillanceIvo I de Vos, Daan Nieboer, Mark Frydenberg, et al.
Translational Andrology and Urology|March 14, 2023
Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk CalculatorIvo I de Vos, Frank-Jan H Drost, Leonard P Bokhorst, et al.
European Urology Open Science|December 6, 2024
Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam DataSebastiaan Remmers, Ivo I de Vos, Frederique B Denijs, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Personalized Medicine|April 28, 2023
Active Surveillance for Prostate Cancer: Past, Current, and Future TrendsIvo I de Vos, Henk B Luiting, Monique J Roobol
European Urology|November 2, 2023
Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer RotterdamIvo I de Vos, Sebastiaan Remmers, Renée Hogenhout, et al.
European Urology|April 7, 2023
A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate CancerIvo I de Vos, Annick Meertens, Renée Hogenhout, et al.
European Urology Oncology|September 10, 2023
From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of LifeRenée Hogenhout, Sebastiaan Remmers, Marlies E van Slooten-Midderigh, et al.
European Urology Open Science|August 1, 2022
Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer RotterdamRenée Hogenhout, Ivo I de Vos, Sebastiaan Remmers, et al.
European Urology Oncology|November 27, 2024
Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer RotterdamIvo I de Vos, Charlotte Rosenstand, Renée Hogenhout, et al.
European Urology Open Science|April 14, 2025
Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller TumorsLisa J Kroon, Ivo I de Vos, Charlotte F Kweldam, et al.
JAMA Network Open|January 17, 2025
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active SurveillanceIvo I de Vos, Daan Nieboer, Mark Frydenberg, et al.
Translational Andrology and Urology|March 14, 2023
Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk CalculatorIvo I de Vos, Frank-Jan H Drost, Leonard P Bokhorst, et al.
European Urology Open Science|December 6, 2024
Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam DataSebastiaan Remmers, Ivo I de Vos, Frederique B Denijs, et al.
Pageof 2